154 related articles for article (PubMed ID: 37914960)
1. SLC38A5 promotes glutamine metabolism and inhibits cisplatin chemosensitivity in breast cancer.
Shen X; Wang G; He H; Shang P; Yan B; Wang X; Shen W
Breast Cancer; 2024 Jan; 31(1):96-104. PubMed ID: 37914960
[TBL] [Abstract][Full Text] [Related]
2. Expression and function of SLC38A5, an amino acid-coupled Na+/H+ exchanger, in triple-negative breast cancer and its relevance to macropinocytosis.
Ramachandran S; R Sennoune S; Sharma M; Thangaraju M; V Suresh V; Sneigowski T; D Bhutia Y; Pruitt K; Ganapathy V
Biochem J; 2021 Nov; 478(21):3957-3976. PubMed ID: 34704597
[TBL] [Abstract][Full Text] [Related]
3. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer.
Kim MJ; Kim HS; Kang HW; Lee DE; Hong WC; Kim JH; Kim M; Cheong JH; Kim HJ; Park JS
Cells; 2023 Oct; 12(20):. PubMed ID: 37887353
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of circular RNA septin 9 inhibits the malignant progression of breast cancer by reducing the expression of solute carrier family 1 member 5 in a microRNA-149-5p-dependent manner.
Wang J; Yang K; Cao J; Li L
Bioengineered; 2021 Dec; 12(2):10624-10637. PubMed ID: 34738502
[TBL] [Abstract][Full Text] [Related]
5. Amino acid transporter SLC38A5 regulates developmental and pathological retinal angiogenesis.
Wang Z; Yemanyi F; Blomfield AK; Bora K; Huang S; Liu CH; Britton WR; Cho SS; Tomita Y; Fu Z; Ma JX; Li WH; Chen J
Elife; 2022 Dec; 11():. PubMed ID: 36454214
[TBL] [Abstract][Full Text] [Related]
6. Amino acid transporter SLC38A5 is a tumor promoter and a novel therapeutic target for pancreatic cancer.
Sniegowski T; Rajasekaran D; Sennoune SR; Sunitha S; Chen F; Fokar M; Kshirsagar S; Reddy PH; Korac K; Mahmud Syed M; Sharker T; Ganapathy V; Bhutia YD
Sci Rep; 2023 Oct; 13(1):16863. PubMed ID: 37803043
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of cannabinoid receptor 2 is associated with human breast cancer proliferation, apoptosis, chemosensitivity and prognosis via the PI3K/Akt/mTOR signaling pathway.
Song Q; Zhang W; Shi D; Zhang Z; Zhao Q; Wang M; Huang M; Meng J; Cui W; Luo X
Cancer Med; 2023 Jun; 12(12):13538-13550. PubMed ID: 37220224
[TBL] [Abstract][Full Text] [Related]
8. Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β‑catenin silencing.
Zhu X; Feng J; Fu W; Shu X; Wan X; Liu J
Int J Mol Med; 2020 Jun; 45(6):1838-1850. PubMed ID: 32186756
[TBL] [Abstract][Full Text] [Related]
9. RBM8A Depletion Decreases the Cisplatin Resistance and Represses the Proliferation and Metastasis of Breast Cancer Cells via AKT/mTOR Pathway.
Song T; Zhang H
Breast J; 2022; 2022():4576789. PubMed ID: 36105365
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of BUBR1 regulates the proliferation and cell cycle of breast cancer cells and increases the sensitivity of cells to cisplatin.
Lu Y; Wang R; He S; Zhang Q; Wei J; Hu J; Ding Y
In Vitro Cell Dev Biol Anim; 2023 Dec; 59(10):778-789. PubMed ID: 38048028
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin.
Zhang X; Zhang Y; Liu X; Fang A; Li P; Li Z; Liu T; Yang Y; Du L; Wang C
PLoS One; 2015; 10(11):e0143441. PubMed ID: 26599571
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer.
Jiang CF; Shi ZM; Li DM; Qian YC; Ren Y; Bai XM; Xie YX; Wang L; Ge X; Liu WT; Zhen LL; Liu LZ; Jiang BH
Mol Cancer; 2018 Apr; 17(1):83. PubMed ID: 29685157
[TBL] [Abstract][Full Text] [Related]
13. Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression.
Liang G; Ling Y; Mehrpour M; Saw PE; Liu Z; Tan W; Tian Z; Zhong W; Lin W; Luo Q; Lin Q; Li Q; Zhou Y; Hamai A; Codogno P; Li J; Song E; Gong C
Mol Cancer; 2020 Mar; 19(1):65. PubMed ID: 32213200
[TBL] [Abstract][Full Text] [Related]
14. Silencing of lncRNA PART1 inhibits proliferation, invasion and migration of breast cancer cells and promotes the efficacy of cisplatin in breast cancer cells.
Zhang L; Zhang J; Ni C
Gen Physiol Biophys; 2020 Jul; 39(4):343-354. PubMed ID: 32700682
[TBL] [Abstract][Full Text] [Related]
15. The
Taurino G; Chiu M; Bianchi MG; Griffini E; Bussolati O
Am J Physiol Cell Physiol; 2023 Aug; 325(2):C550-C562. PubMed ID: 37458433
[No Abstract] [Full Text] [Related]
16. Circ-UBR1 facilitates proliferation, metastasis, and inhibits apoptosis in breast cancer by regulating the miR-1299/CCND1 axis.
Zhang L; Sun D; Zhang J; Tian Y
Life Sci; 2021 Feb; 266():118829. PubMed ID: 33259864
[TBL] [Abstract][Full Text] [Related]
17. miR-141-3p Promotes the Cisplatin Sensitivity of Osteosarcoma Cell through Targeting the Glutaminase [GLS]-Mediated Glutamine Metabolism.
Zhou X; Wei P; Wang X; Zhang J; Shi Y
Curr Mol Med; 2023; 23(2):177-184. PubMed ID: 34607540
[TBL] [Abstract][Full Text] [Related]
18. Long Non-Coding RNA TFAP2A-AS1 Inhibits Cell Proliferation and Invasion in Breast Cancer via miR-933/SMAD2.
Zhou B; Guo H; Tang J
Med Sci Monit; 2019 Feb; 25():1242-1253. PubMed ID: 30768589
[TBL] [Abstract][Full Text] [Related]
19. Circ_0062558 promotes growth, migration, and glutamine metabolism in triple-negative breast cancer by targeting the miR-876-3p/SLC1A5 axis.
Yuan M; Zhang J; He Y; Yi G; Rong L; Zheng L; Zhan T; Zhou C
Arch Gynecol Obstet; 2022 Nov; 306(5):1643-1655. PubMed ID: 35284960
[TBL] [Abstract][Full Text] [Related]
20. miR-100 Reverses Cisplatin Resistance in Breast Cancer by Suppressing HAX-1.
Wu G; Zhou W; Pan X; Sun Y; Xu H; Shi P; Li J; Gao L; Tian X
Cell Physiol Biochem; 2018; 47(5):2077-2087. PubMed ID: 29975932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
